Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert ...
Baylor Scott & White The Heart Hospital-Plano in Texas cut times of cardiogenic shock diagnosis in half after implementing a quality improvement project that included nurse education and an ...
MyChesCo on MSN1mon
Windtree Therapeutics Begins SEISMiC C Trial for Advanced Cardiogenic ShockSCAI Stage C cardiogenic shock is characterized by significant organ hypoperfusion, necessitating the use of inotropic or ...
Zacks Small Cap Research on MSN2mon
WINT: Lead Drug Candidates, Multiple Programs, Several Upcoming Expected MilestonesAmong the various upcoming milestones the company expects to report results from its small Phase 2 cardiogenic shock SCAI ...
Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a biotechnology company focused on advancing early and late-stage innovative therapies for critical conditions and diseases, ...
By this stage the differential diagnosis had shifted ... typically present with hypotension, cardiomyopathy, or cardiogenic shock when β-adrenergic stimulation overrides α-adrenergic stimulation.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback